ReviewPharmacoEconomics2015

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.

Nigel Fleeman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.